enGene Overview

  • Founded
  • 1999
Founded
  • Status
  • Private
  • Employees
  • 62
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 8

enGene General Information

Description

Developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.

Contact Information

Website
www.engene.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 7171 Frederick-Banting
  • Montreal, Quebec H4S 1Z9
  • Canada
+1 (514) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

enGene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 000.00 Completed Generating Revenue
7. Later Stage VC 18-Jan-2019 000.00 Completed Generating Revenue
6. Corporate 01-Mar-2017 00000 000.00 Completed Generating Revenue
5. Later Stage VC (Series B) 26-Jan-2015 000.00 000.00 Completed Generating Revenue
4. Later Stage VC 01-Aug-2013 000.00 000.00 Completed Generating Revenue
3. Grant 10-Jun-2009 00000 00.00 Completed Generating Revenue
2. Later Stage VC (Series A) 17-Mar-2008 $6.4M $8.5M Completed Generating Revenue
1. Seed Round 15-Aug-2001 $2.1M $2.1M Completed Generating Revenue
To view enGene’s complete valuation and funding history, request access »

enGene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's m
Biotechnology
Montreal, Canada
62 As of 2021
000.00
000000 - 000 000.00

0000 000

veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute
0000000000000
Santa Monica, CA
000 As of 0000
00000
000 0000-00-00
000000&0 00000

0000000

uip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum d
0000000000000
Cambridge, MA
00 As of 0000
00000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

enGene Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kite Pharma Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000 0000000000 Formerly VC-backed Miramar, FL 00 00000 000000&0 00000
You’re viewing 5 of 26 competitors. Get the full list »

enGene Executive Team (14)

Name Title Board Seat Contact Info
Jason Hanson JD Chief Executive Officer, President and Board Member
Anthony Cheung Ph.D Co-Founder, Chief Technology Officer and Board Member
José Lora Ph.D Chief Scientific Officer
John Brown Ph.D Owner & Director
Timothy Kieffer Ph.D Co-Founder & Vice President, Research
You’re viewing 5 of 14 executive team members. Get the full list »

enGene Board Members (12)

Name Representing Role Since
Brian Underdown Ph.D Lumira Ventures Board Member 000 0000
Dennis Langer MD Self Vice Chairman 000 0000
Gerry Brunk Lumira Ventures Board Member 000 0000
Marco Boorsma Ph.D FORBION Board Member 000 0000
Paul Erickson Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

enGene Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

enGene Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Fonds de solidarité FTQ PE/Buyout Minority 000 0000 000000 0
FORBION Venture Capital Minority 000 0000 000000 0
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority 000 0000 000000 0
Pharmstandard Corporation Minority 000 0000 000000 0
phs Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »